サンプル依頼リスト カート
  • English
  • Korean
表紙：抗うつ薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1345462

抗うつ薬の世界市場-2023年～2030年

Global Antidepressant Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
抗うつ薬の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

抗うつ薬の世界市場は2022年に143億米ドル、2030年には206億米ドルに達すると予測されています。

抗うつ薬は、気分や感情に関連するセロトニンやノルアドレナリンなどの神経伝達物質と呼ばれる脳内化学物質のレベルを上昇させることによって作用します。抗うつ薬は、大うつ病性障害、不安障害、月経前不快気分障害（PMDD）、双極性うつ病の治療に用いられます。

抗うつ薬はうつ病の初期治療として処方されることが多く、他の治療法や運動療法と併用して症状を管理することもできます。SSRI（選択的セロトニン再取り込み阻害薬）は最も一般的に処方される抗うつ薬です。セロトニンの不均衡はうつ病に関与する可能性があり、これらの薬剤は脳内のセロトニン再取り込みを減少させることでうつ病の症状と闘います。

さらに、製品承認の増加、うつ病性障害に対する認識、研究開発などの重要な成長要因が、将来の市場成長をもたらします。Eli Lilly and Company、GlaxoSmithKline Plc.、LGM Pharma LLC、Apotex Inc.などの主要企業が市場で活発に活動しています。

ダイナミクス

抗うつ薬の研究開発の増加

世界の抗うつ薬市場は、最近の様々な研究開発により大きな成長を遂げています。うつ病は通常、病歴や臨床所見、画像所見に基づいて診断されます。また、大うつ病性障害の治療における先進的な研究開発は、市場の成長を加速させるのに役立ちます。

例えば、2023年8月、ノバルティスAGは、治療抵抗性うつ病の治療薬Onfasprodilを臨床開発フェーズII中であると宣言しました。オンファスプロジル（MIJ-821）は、治療抵抗性うつ病、大うつ病性障害（MDD）の治療に使用されます。

さらに、ヤンセンファーマは2022年11月、治療抵抗性大うつ病性障害（TRD）の成人患者を対象に、フレキシブルに投与可能なスプラバトとクエチアピン徐放製剤（XR）を比較し、短期および長期の有効性、安全性、忍容性を評価するためにデザインされた長期無作為化非盲検第3b相試験であるESCAPE-TRDの結果を発表しました。

本データによると、スプラバトを投与された治療抵抗性大うつ病性障害（TRD）の成人は、試験開始6週目から有意に高い寛解率を達成し、試験開始15日目には奏効率を示しました。このように、上記の要因により、市場は予測期間中に拡大すると予想されます。

抗うつ薬の承認の増加

抗うつ薬の世界市場は、規制プロセスの合理化、技術革新の促進、患者による治療へのアクセスの改善、新規かつ効率的なうつ病治療の選択肢の世界の普及を促進する医薬品承認手続きの進歩によって牽引されると予測されます。

例えば、Biogen Inc.とSage Therapeutics, Inc.の共同声明によると、2023年2月、FDAは大うつ病性障害（MDD）と産後うつ病（PPD）の治療薬としてズラノロンの新薬承認申請（NDA）を承認しました。成人のMDDおよびPPD患者を対象に、治験薬ズラノロンが1日1回、14日間投与されます。

2021年12月、Dr. Reddy's Laboratories社はVenlafaxine ER錠の米国食品医薬品局（USFDA）の承認を取得しました。本剤は選択的セロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）であり、Venlafaxine Extended Release錠は大うつ病性障害（MDD）および社会不安障害（SAD）に適応があります。

治療薬に伴う副作用が市場の成長を妨げる

抗うつ薬はうつ病の治療によく効きますが、吐き気、体重増加、性機能障害、ごく一部のケースでは自殺念慮のリスクが高くなるなどの不快な副作用もあります。抗うつ薬の使用は、特に特定の患者集団において、これらの安全性の問題を厳密にモニタリングし評価する必要性によって制限される可能性があります。

さらに、抗うつ薬にはあまり知られていない副作用があります。その中には、アルコールに対する耐性の低下、血小板凝固への影響による出血リスクの上昇、頭痛や錯乱のような症状を引き起こす可能性のある血中ナトリウム濃度への潜在的な干渉などがあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 抗うつ薬の研究開発の増加
      • 抗うつ薬の承認の増加
    • 抑制要因
      • 治療薬に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析
  • DMIの見解

第6章 COVID-19分析

第7章 薬剤クラス別

  • モノアミン酸化酵素阻害薬
    • イソカルボキサジド
    • フェネルジン
    • セレギリン
    • トラニルシプロミン
  • ノルエピネフリン・ドパミン再取り込み阻害薬
    • アミネプチン
    • ブプロピオン
    • デソキシピプラドロール
    • デクスメチルフェニデート
    • ジフェメトレックス
  • セロトニン・ノルエピネフリン再取り込み阻害薬
    • デスベンラファキシン
    • デュロキセチン
    • レボミルナシプラン
    • ミルナシプラン
    • ベンラファキシン
  • 選択的セロトニン再取り込み阻害薬
    • シタロプラム
    • エスシタロプラム
    • フルオキセチン
    • パロキセチン
    • セルトラリン
  • 三環系抗うつ薬
    • アミトリプチリン
    • アモキサピン
    • デシプラミン
    • ドキセピン
    • イミプラミン
    • ノルトリプチリン
    • その他

第8章 うつ病の疾患別

  • 大うつ病性障害
  • 強迫性障害
  • 全般性不安障害
  • パニック障害
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な動向と戦略

第12章 企業プロファイル

  • Eli Lilly and Company
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • GlaxoSmithKline Plc.
  • LGM Pharma LLC
  • Apotex Inc.
  • Zheijiang Huahai Pharmaceutical Co. Ltd.
  • AstraZeneca Plc.
  • Takeda Pharmaceutical Co. Ltd
  • Pfizer Inc.
  • Aurobindo Pharma Limited
  • Merck KGaA

第13章 付録

目次
Product Code: PH1787

Overview

Global Antidepressant Drugs Market reached US$ 14.3 billion in 2022 and is expected to reach US$ 20.6 billion by 2030.

Antidepressant drugs work by increasing levels of chemicals in the brain called neurotransmitters such as serotonin and noradrenaline that are linked to mood and emotion. Antidepressants are used to treat major depressive disorder, anxiety disorders, premenstrual dysphoric disorder (PMDD), and bipolar depression.

Antidepressants are often prescribed as the initial treatment for depression and can be used with other forms of therapy and exercise to manage symptoms. SSRIs (Selective serotonin reuptake inhibitors) are the most commonly prescribed class of antidepressants. An imbalance of serotonin can play a role in depression and these drugs fight depression symptoms by decreasing serotonin reuptake in the brain.

Furthermore, significant growth drivers such as increasing product approvals, awareness of depressive disorders, and research and developments give rise to future market growth. Significant key players like Eli Lilly and Company, GlaxoSmithKline Plc., LGM Pharma LLC, Apotex Inc., and others are actively operating in the market.

Dynamics

Increasing Research and Developments for Antidepressant Drugs

The global antidepressant drugs market has witnessed significant growth due to various recent research and developments. Depression is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating major depressive disorder help to accelerate market growth.

For instance, in August 2023, Novartis AG declared that the drug Onfasprodil is under clinical development Phase II for Treatment Resistant Depression. Onfasprodil (MIJ-821) is used for the treatment of treatment-resistant depression, and major depressive disorder (MDD).

Additionally, in November 2022, Janssen Pharmaceutical declared the results from ESCAPE-TRD, a long-term, randomized, open-label phase 3b designed to evaluate the short- and long-term efficacy, safety and tolerability of flexibly dosed SPRAVATO compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor (SSRI) in adults with treatment-resistant major depressive disorder (TRD).

The data shows that adults with treatment-resistant major depressive disorder (TRD) treated with SPRAVATO achieved significantly higher remission rates from Week 6 and response rates as early as day 15 in the study. Thus, due to the above factors, the market is expected to boost over the forecast period.

Increasing Approvals for Antidepressant Drugs

The global market for antidepressant drugs is anticipated to be driven by advancements in drug approval procedures which will streamline regulatory processes, stimulate innovation, improve patient access to therapies, and facilitate the availability of novel and efficient depression management choices globally.

For instance, in February 2023, the FDA approved the submission of a New Drug Application (NDA) for zuranolone for the treatment of major depressive disorder (MDD) and postpartum depression (PPD), according to a joint statement from Biogen Inc. and Sage Therapeutics, Inc. Adults with MDD and PPD are being treated with the investigational drug zuranolone once daily for 14 days.

In December 2021, Dr. Reddy's Laboratories received U.S. Food and Drug Administration (USFDA) approval for Venlafaxine ER Tablets. It is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and Venlafaxine Extended Release tablets are indicated for major depressive disorder (MDD) and social anxiety disorder (SAD).

Side Effects Associated with Treatment Drugs will Hamper the Growth of the Market

Antidepressant medications work well to treat depression, but they can also have unpleasant side effects like nausea, weight gain, sexual dysfunction, and, in a small percentage of cases, a higher risk of suicidal thoughts. Antidepressant drug uptake may be constrained by the need for rigorous monitoring and evaluation of these safety issues, particularly in certain patient populations.

In addition, antidepressant medications have fewer well-known adverse effects. Among them are a decreased tolerance to alcohol, a raised risk of bleeding due to effects on platelet clotting, and potential interference with blood sodium levels, which could cause symptoms like headaches or confusion.

Segment Analysis

The global antidepressant drugs market is segmented based on drug class, depression disorder, distribution channel, and region.

Selective Serotonin Reuptake Inhibitor is expected to hold the largest market share over the period forecast owing to increasing clinical trials of SSRI treatment drugs. A total of 933 clinical trials were performed for the treatment of depression. For instance, according to clinicalTrials.gov, on July 13, 2023, the University of Minnesota conducted a clinical trial on the Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression. The purpose of this study is to evaluate the effectiveness of two adaptive treatment strategies (ATSs) for adolescent depression. The intervention involves selective serotonin reuptake inhibitor drugs like Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline.

Additionally, on August 16, 2023, Janssen Research & Development, LLC conducted a clinical trial on the Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder. The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor) in all participants with major depressive disorder (MDD).

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022.

The global antidepressant drugs market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the antidepressant drugs market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising FDA approvals, and research and developments in antidepressant drugs.

For instance, in August 2022, Axsome Therapeutics, Inc., a biopharmaceutical company specializing in novel therapeutics for central nervous system (CNS) disorders, got FDA approval for AUVELITY (dextromethorphan HBr - bupropion HCl) extended-release tablets. With this approval, AUVELITY becomes the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for the treatment of major depressive disorder (MDD) in adults.

Additionally, in December 2022, the FDA approved VRAYLAR (cariprazine) as an adjuvant therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, according to AbbVie. Cariprazine is marketed as VRAYLAR in the U.S., and it is FDA-approved to treat adults with depressive, acute manic, and mixed episodes associated with bipolar I disorder, as well as schizophrenia, in addition to being approved as an adjunctive therapy to antidepressants for treatment of MDD.

Competitive Landscape

The major global players in the market include: Eli Lilly and Company, GlaxoSmithKline Plc., LGM Pharma LLC, Apotex Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd, Pfizer Inc., Aurobindo Pharma Limited, and Merck KGaA among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global antidepressant drugs market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in antidepressant drug research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the antidepressant drugs market.

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the antidepressant drugs market is expected to be moderately affected over the forecast period.

By Drug Class

  • Monoamine Oxidase Inhibitors
    • Isocarboxazid
    • Phenelzine
    • Selegiline
    • Tranylcypromine
  • Norepinephrine-Dopamine Reuptake Inhibitor
    • Amineptine
    • Bupropion
    • Desoxypipradrol
    • Dexmethylphenidate
    • Difemetorex
  • Serotonin-Norepinephrine Reuptake Inhibitors
    • Desvenlafaxine
    • Duloxetine
    • Levomilnacipran
    • Milnacipran
    • Venlafaxine
  • Selective Serotonin Reuptake Inhibitors
    • Citalopram
    • Escitalopram
    • Fluoxetine
    • Paroxetine
    • Sertraline
  • Tricyclic Antidepressants
    • Amitriptyline
    • Amoxapine
    • Desipramine
    • Doxepin
    • Imipramine
    • Nortriptyline
    • By Depression Disorder
  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2023, Alembic Pharmaceuticals received approval from the US Food & Drug Administration to market Brexpiprazole tablets in strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. Brexpiprazole tablets are indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.
  • In November 2022, Luye Pharma Group received marketing approval from China's NMPA for the triple monoamine reuptake inhibitor Ruoxinlin (toludesvenlafaxine hydrochloride) to treat patients with major depressive disorder.

Why Purchase the Report?

  • To visualize the global antidepressant drugs market segmentation based on drug class, depression disorder, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global antidepressant drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global antidepressant drugs market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Depression Disorder
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Research and Developments for Antidepressant Drugs
      • 4.1.1.2. Increasing Approvals for Antidepressant Drugs
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with Treatment Drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Monoamine Oxidase Inhibitors
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Isocarboxazid
    • 7.2.4. Phenelzine
    • 7.2.5. Selegiline
    • 7.2.6. Tranylcypromine
  • 7.3. Norepinephrine-Dopamine Reuptake Inhibitor
    • 7.3.1. Amineptine
    • 7.3.2. Bupropion
    • 7.3.3. Desoxypipradrol
    • 7.3.4. Dexmethylphenidate
    • 7.3.5. Difemetorex
  • 7.4. Serotonin-Norepinephrine Reuptake Inhibitors
    • 7.4.1. Desvenlafaxine
    • 7.4.2. Duloxetine
    • 7.4.3. Levomilnacipran
    • 7.4.4. Milnacipran
    • 7.4.5. Venlafaxine
  • 7.5. Selective Serotonin Reuptake Inhibitors
    • 7.5.1. Citalopram
    • 7.5.2. Escitalopram
    • 7.5.3. Fluoxetine
    • 7.5.4. Paroxetine
    • 7.5.5. Sertraline
  • 7.6. Tricyclic Antidepressants
    • 7.6.1. Amitriptyline
    • 7.6.2. Amoxapine
    • 7.6.3. Desipramine
    • 7.6.4. Doxepin
    • 7.6.5. Imipramine
    • 7.6.6. Nortriptyline
    • 7.6.7. Others

8. By Depression Disorder

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 8.1.2. Market Attractiveness Index, By Depression Disorder
  • 8.2. Major Depressive Disorder
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Obsessive-Compulsive Disorder
  • 8.4. Generalized Anxiety Disorder
  • 8.5. Panic Disorder
  • 8.6. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacy
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Product Benchmarking
  • 11.3. Company Share Analysis
  • 11.4. Key Developments and Strategies

12. Company Profiles

  • 12.1. Eli Lilly and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. GlaxoSmithKline Plc.
  • 12.3. LGM Pharma LLC
  • 12.4. Apotex Inc.
  • 12.5. Zheijiang Huahai Pharmaceutical Co. Ltd.
  • 12.6. AstraZeneca Plc.
  • 12.7. Takeda Pharmaceutical Co. Ltd
  • 12.8. Pfizer Inc.
  • 12.9. Aurobindo Pharma Limited
  • 12.10. Merck KGaA

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us